Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo

@article{Versiani1990TolerabilityOM,
  title={Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo},
  author={M{\'a}rcio Versiani and Antonio Eg{\'i}dio Nardi and Ivan Figueira and Max Stabl},
  journal={Acta Psychiatrica Scandinavica},
  year={1990},
  volume={82}
}
Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies. Pooled data from these studies, comprising 1656 patients, as well as the consideration of individual trials, show that moclobemide is far better tolerated than the TCAs. Its side effects mainly comprise mild degrees of nausea and dizziness at the beginning of treatment in a small proportion of patients. Age and sex… Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
A review of the reversible MAO‐A inhibitor moclobemide in geriatric patients
TLDR
A comparison of the relevant literature shows that moclobemide has advantages over other, classic, antidepressants because of better tolerability, fewer side effects and interactions, shorter latency of effect, and lower toxicity. Expand
Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
TLDR
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression
TLDR
A series of meta-analyses of studies of the two most widely researched RIMAs, moclobemide (MOC; Aurorex) and brofaromine (BRO) confirm that both BRO and MOC are as effective as the tricyclic antidepressants, and they are better tolerated. Expand
Moclobemide safety: monitoring a newly developed product in the 1990s.
TLDR
The safety profile of the product after 3 years on world markets is presented, largely unchanged from those observed at 1 and 2 years postlaunch, when the estimated exposed populations were 168,000 and 328,000, respectively. Expand
Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors
TLDR
Overall, RIMAs appear to represent therapeutic progress in the treatment of depression in terms of both efficacy and tolerability. Expand
Newer and Older Monoamine Oxidase Inhibitors
SummaryMonoamine oxidase (MAO) inhibitors (MAOIs) available at present can be classified into 3 types: (i) older, irreversible nonselective (first generation) agents such as phenelzine,Expand
Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III)
TLDR
While both treatments were well tolerated, moclobemide showed a more favourable side-effect profile than fluvoxamine, and showed a marked antidepressant effect. Expand
Pharmacotherapy of dysthymia: review and new findings.
TLDR
The controlled studies with tricyclics, MAOIs, reversible inhibitors of monoamine oxidase (RIMAs), specific serotonin reuptake inhibitor (SSRIs) or benzamides showed that drugs well-tolerated work better in dysthymia, due to the fact that the treatment must be long-term. Expand
Moclobemide and fluvoxamine co‐administration: A prospective study in healty volunteers to investigate the potential development of the ‘serotonin syndrome’
TLDR
The combined administration of moclobemide, a novel, selective and reversible inhibitor of MAO‐A and fluvoxamine, a selective serotonin re‐uptake inhibitor, was studied in 25 healthy male volunteers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 14 REFERENCES
Moclobemide and clomipramine in the treatment of depression
TLDR
Because of its low toxicity, good tolerance, its selectivity and reversibility moclobemide may be a better alternative than the older monoamine oxidase inhibitors. Expand
Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression
TLDR
The design and the main therapeutic results of 3 controlled double‐blind studies comparing moclobemide with tricyclics and/or placebo in depressed patients are presented and it is shown that reversible inhibitors of MAO‐A demonstrate good efficacy independently of the diagnostic category of depression. Expand
Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
TLDR
moclobemide seemed to be more effective in retarded depressives, maprotiline was superior in alleviating depressive agitation and sleep disturbances, and compared to tricyclic antidepressants a high CSF/plasma ratio could be detected. Expand
Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
TLDR
When the tolerability of moclobemide, as judged by reported and observed adverse events, is compared to that of placebo, it appears that only nausea is reported significantly more frequently with moclOBemide than with placebo; in particular the incidence of anticholinergic side effects was low with mclobemides and was significantly higher with the TCAs. Expand
Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a majorExpand
A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.
TLDR
A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder, and proved to be a well-tolerated and effective antidepressant. Expand
A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness.
TLDR
A double blind comparative study of amitriptyline and a new reversible MAO A inhibitor R011-1163 was conducted in 25 depressed inpatients over 4 weeks with side effects of mild to moderate severity. Expand
Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
TLDR
It is pointed to that moclobemide may be the true "second generation antidepressant", comparably efficacious to the traditional compounds, producing far less side-effects, and because it is reversible, not requiring dietary or drug restrictions in clinical practice. Expand
Double‐blind comparison of moclobemide, imipramine and placebo in depressive patients
TLDR
It is concluded that both moclobemide and imipramine were superior to placebo in treatment of major depressive episodes in outpatients and the clinical response was maintained and the long‐term treatment was well tolerated. Expand
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine. Expand
...
1
2
...